ArticleReviews in urology2009
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.
Article in Reviews in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.Acta neuropathologica · 2024Trial
- Topical use of Matricaria recutita L (Chamomile) Oil in the Treatment of Monosymptomatic Enuresis in Children: A Double-Blind Randomized Controlled Trial.Journal of evidence-based complementary & alternative medicine · 2017Trial
- The Influence of Occlusion on Oxybutynin Absorption from Gel-Deposited Excipients Using Ex Vivo Skin and Healthy Human Volunteers.The AAPS journal · 2026Article
- Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?Advances in urology · 2018Article
- An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.Therapeutic advances in urology · 2016Review
- Update on the management of overactive bladder: patient considerations and adherence.Open access journal of urology · 2010Review
- Management of overactive bladder.Nature reviews. Urology · 2010Review
- Will the evolution of overactive bladder delivery systems increase patient compliance?Reviews in urology · 2009Article
- Defining efficacy in the treatment of overactive bladder syndrome.Reviews in urology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple antimuscarinic agents are available for the treatment of overactive bladder. Many of the agents have undergone reformulation in an attempt to improve patient adherence and drug tolerability. Oxybutynin evolved from an immediate-release pill to a once-daily oral preparation, and is now available as a transdermal patch and gel. This article discusses the clinical impact of oxybutynin reformulation and reviews the evolution and benefits of transdermal therapy.
Indexed as
Identifiers
19390669PMC2668835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.